Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GLTO | US
-0.09
-1.26%
Healthcare
Biotechnology
30/06/2024
21/10/2024
7.03
7.08
7.08
6.84
Galecto Inc. a clinical-stage biotechnology company develops molecules for the treatment of fibrosis cancer inflammation and other related diseases. The company's lead product candidate is GB2064 which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139 an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases such as idiopathic pulmonary fibrosis a life-threatening progressive fibrotic disease of the lung; GB2064 a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211 a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer as well as in Phase Ib/IIa for fibrosis. Galecto Inc. was founded in 2011 and is headquartered in Copenhagen Denmark.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
144.6%1 month
114.4%3 months
89.5%6 months
76.2%-
-
0.37
0.00
0.00
0.46
-
-
-21.91M
9.22M
9.22M
-
-
-
-
-75.57
0.27
1.23
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.80
Range1M
6.77
Range3M
14.36
Rel. volume
0.18
Price X volume
57.77K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
VIRACTA THERAPEUTICS INC | VIRX | Biotechnology | 0.24 | 9.46M | 4.44% | n/a | 704.57% |
BioCardia Inc | BCDA | Biotechnology | 2.68 | 9.39M | -0.37% | n/a | -58.03% |
Aptorum Group Limited | APM | Biotechnology | 1.7 | 9.30M | -0.58% | n/a | 13.53% |
Arsanis Inc | ASNS | Biotechnology | 1.38 | 8.30M | -4.83% | n/a | 252.35% |
Plus Therapeutics Inc | PSTV | Biotechnology | 1.4 | 8.25M | -2.78% | n/a | -45.04% |
Soligenix Inc | SNGX | Biotechnology | 3.59 | 8.19M | -7.12% | n/a | 84.28% |
TFFP | TFFP | Biotechnology | 2.3 | 7.97M | 11.11% | n/a | 1.26% |
Alzamend Neuro Inc. Common Stock | ALZN | Biotechnology | 1.73 | 7.74M | 3.28% | n/a | 0.00% |
Moleculin Biotech Inc | MBRX | Biotechnology | 2.67 | 7.59M | 3.29% | n/a | 3.00% |
Pulmatrix Inc | PULM | Biotechnology | 2.04 | 7.45M | 0.97% | n/a | 0.18% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.46 | 0.53 | Par |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 0.37 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 89.48 | 72.80 | Riskier |
Debt to Equity | 0.00 | -1.23 | Expensive |
Debt to Assets | 0.00 | 0.25 | Cheaper |
Market Cap | 9.22M | 3.66B | Emerging |